DECOY THERAPEUTICS INC (DCOY) Fundamental Analysis & Valuation

NASDAQ:DCOY • US79400X6022

Current stock price

6.2 USD
+0.13 (+2.14%)
Last:

This DCOY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. DCOY Profitability Analysis

1.1 Basic Checks

  • DCOY had negative earnings in the past year.
  • In the past year DCOY has reported a negative cash flow from operations.
  • DCOY had negative earnings in each of the past 5 years.
  • DCOY had a negative operating cash flow in each of the past 5 years.
DCOY Yearly Net Income VS EBIT VS OCF VS FCFDCOY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • DCOY has a Return On Assets of -113.22%. This is in the lower half of the industry: DCOY underperforms 79.07% of its industry peers.
  • With a Return On Equity value of -212.57%, DCOY is not doing good in the industry: 71.12% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -113.22%
ROE -212.57%
ROIC N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
DCOY Yearly ROA, ROE, ROICDCOY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for DCOY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DCOY Yearly Profit, Operating, Gross MarginsDCOY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. DCOY Health Analysis

2.1 Basic Checks

  • DCOY has more shares outstanding than it did 1 year ago.
  • DCOY has more shares outstanding than it did 5 years ago.
  • DCOY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DCOY Yearly Shares OutstandingDCOY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10K 20K 30K 40K
DCOY Yearly Total Debt VS Total AssetsDCOY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -12.17, we must say that DCOY is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -12.17, DCOY is not doing good in the industry: 77.33% of the companies in the same industry are doing better.
  • DCOY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.17
ROIC/WACCN/A
WACCN/A
DCOY Yearly LT Debt VS Equity VS FCFDCOY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • DCOY has a Current Ratio of 2.13. This indicates that DCOY is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.13, DCOY is doing worse than 76.16% of the companies in the same industry.
  • A Quick Ratio of 2.13 indicates that DCOY has no problem at all paying its short term obligations.
  • DCOY has a Quick ratio of 2.13. This is in the lower half of the industry: DCOY underperforms 73.84% of its industry peers.
Industry RankSector Rank
Current Ratio 2.13
Quick Ratio 2.13
DCOY Yearly Current Assets VS Current LiabilitesDCOY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. DCOY Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 55.51% over the past year.
EPS 1Y (TTM)55.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-126.98%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DCOY Yearly Revenue VS EstimatesDCOY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2026 2M 4M 6M 8M 10M
DCOY Yearly EPS VS EstimatesDCOY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 -500K -1M -1.5M -2M

More info and screens

Find the best growth stocksShow best growing peers

0

4. DCOY Valuation Analysis

4.1 Price/Earnings Ratio

  • DCOY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DCOY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DCOY Price Earnings VS Forward Price EarningsDCOY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DCOY Per share dataDCOY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -200 -400

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DCOY Dividend Analysis

5.1 Amount

  • No dividends for DCOY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DCOY Fundamentals: All Metrics, Ratios and Statistics

DECOY THERAPEUTICS INC

NASDAQ:DCOY (4/14/2026, 6:57:56 PM)

6.2

+0.13 (+2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31
Earnings (Next)05-12
Inst Owners12.35%
Inst Owner ChangeN/A
Ins Owners0.59%
Ins Owner ChangeN/A
Market Cap3.29M
Revenue(TTM)N/A
Net Income(TTM)-12.52M
Analysts43.33
Price Target30.6 (393.55%)
Short Float %N/A
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1100%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-593.79
EYN/A
EPS(NY)-9.35
Fwd EYN/A
FCF(TTM)-8.54
FCFYN/A
OCF(TTM)-8.54
OCFYN/A
SpS0
BVpS11.11
TBVpS11.11
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -113.22%
ROE -212.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.13
Quick Ratio 2.13
Altman-Z -12.17
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.73%
EPS Next Y-126.98%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.77%
OCF growth 3YN/A
OCF growth 5YN/A

DECOY THERAPEUTICS INC / DCOY Fundamental Analysis FAQ

What is the fundamental rating for DCOY stock?

ChartMill assigns a fundamental rating of 1 / 10 to DCOY.


What is the valuation status of DECOY THERAPEUTICS INC (DCOY) stock?

ChartMill assigns a valuation rating of 0 / 10 to DECOY THERAPEUTICS INC (DCOY). This can be considered as Overvalued.


What is the profitability of DCOY stock?

DECOY THERAPEUTICS INC (DCOY) has a profitability rating of 0 / 10.


What is the financial health of DECOY THERAPEUTICS INC (DCOY) stock?

The financial health rating of DECOY THERAPEUTICS INC (DCOY) is 5 / 10.


What is the expected EPS growth for DECOY THERAPEUTICS INC (DCOY) stock?

The Earnings per Share (EPS) of DECOY THERAPEUTICS INC (DCOY) is expected to decline by -126.98% in the next year.